


THE PROBLEM

400 millions
people in the world suffer
from allergic rhinitis



10% - 30%
adultos



+40%
children

Allergic rhinitis

Chronic respiratory system disease

Causes sneezing, congestion, itching and runny nose

Comorbidities: asthma, dermatitis and polyp formation



Sleep



Productivity

OUR SOLUTION



Effective

It reduces the levels of IgE, the molecule that triggers allergic episodes.



It is an endogenous protein with very low immunogenicity.



Innovative

RinUb es una proteína de administración oral.

TRL3

Pre - Go to market

- ✓ A single medicine to relieve allergic rhinitis
- ✓ Relief without discomfort
- ✓ Friendly administration

MARKET



FOUNDING TEAM



Dra. Sonia Mayra Pérez Tapia

Executive Director, UDIBI

Specialist in innovation, development, evaluation and regulation of biotechnological products for human use. Collaborator of COFEPRIS in regulation of innovative biotechnological products and cell therapies. Founder and CEO of UDIBI of the IPN.



Dr. Juan Carlos Almagro

Deputy Director, UDIBI

Expert in antibody engineering and development of biological therapies. With more than 25 years of experience in the pharmaceutical industry. Antibody development at Pfizer and Jansen. Founder and CEO of GBI.



Dr. Luis Alberto Vallejo Castillo

Research, Development and Innovation, UDIBI

Specialist in bioequivalence studies, biocomparability and development of biotherapeutic products at the preclinical level.

INVESTMENT

Stage 1 Fundraising

USD \$4,000,000

Financing the cash deficit for the growth plan for the next 18 months of operation.

First round Preclinical studies efficacy/MoA	USD 4,000,000 (26.6%)
Phase I with manufacturing of clinical material	USD 3,000,000 (20.0%)
Clinical phase II and III	USD 8,000,000 (53.4%)

In the next 18 months

1

MoA Efficacy
Characterization

2

Pk/Pd
Laboratories in security studies

3

Safety
Development of GMP manufacturing method

Contact:

Francisco Lozano Martínez
flozano@newgenesis.cl

Raúl Vázquez Cassani
rvazquez@newgenesis.cl